This image shows a lab technician measuring the zone of inhibition during an antibiotic sensitivity test, 1972. The zone of inhibition is measured and compared to a standard in order to determine if an antibiotic is effective in treating the bacterial infection. (Gilda Jones/CDC via Getty Images)

Bio­phar­ma has aban­doned an­tibi­ot­ic de­vel­op­ment. Here’s why we did, too.

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

Tim­ing is Every­thing

When we launched Oc­ta­gon Ther­a­peu­tics in late 2017, I was con­vinced that the time was right for a new an­tibi­ot­ic dis­cov­ery ven­ture. The com­pa­ny was found­ed on im­pres­sive aca­d­e­m­ic pedi­gree and the man­age­ment team had known each oth­er for years. Our first pro­gram was based on a com­pelling ap­proach to tar­get­ing cen­tral me­tab­o­lism in the most dan­ger­ous bac­te­r­i­al pathogens. We had al­ready shown a high lev­el of ef­fi­ca­cy in an­i­mal in­fec­tion mod­els and knew our drug was safe in hu­mans.

At the time, 12 of the largest 18 bio­phar­ma com­pa­nies had aban­doned all an­tibi­ot­ic de­vel­op­ment ef­forts, fo­cus­ing in­stead on dis­ease-mod­i­fy­ing ther­a­pies for chron­ic dis­eases or can­cer. Rather than a neg­a­tive sig­nal, we be­lieved this thin de­vel­op­ment pipeline pre­sent­ed an op­por­tu­ni­ty for small biotechs to fill the void. Week­ly head­lines were scream­ing about the rise of “su­per­bugs,” the mul­ti-drug re­sis­tant bac­te­ria that can­not be treat­ed with ex­ist­ing med­i­cines. Pew Trusts had pub­lished an ex­ten­sive re­por­thigh­light­ing su­per­bugs as the next lead­ing glob­al cause of death, even­tu­al­ly claim­ing more lives than all can­cers com­bined. I was con­vinced that this clear clin­i­cal need would re­sult in re­al re­form in the an­timi­cro­bial de­vel­op­ment space, and that larg­er play­ers would cor­re­spond­ing­ly re-en­ter the mar­ket, hun­gry to pick up first-in-class an­tibi­ot­ic pro­grams.

In ad­di­tion to a clear clin­i­cal need, there had been re­al move­ment on gen­er­at­ing in­cen­tives for an­tibi­ot­ic de­vel­op­ment, and new fund­ing mech­a­nisms were be­com­ing avail­able. The GAIN Act had re­cent­ly been signed in­to law, pro­vid­ing stream­lined re­view and oth­er de­vel­op­ment in­cen­tives for prod­ucts tar­get­ing qual­i­fy­ing pathogens. CARB-X, a pub­lic-pri­vate ef­fort backed by Gates and BAR­DA (and oth­ers), had been cre­at­ed specif­i­cal­ly to fund pre­clin­i­cal an­tibi­ot­ic de­vel­op­ment ef­forts. Ear­ly com­pa­nies re­ceiv­ing mil­lions of dol­lars from CARB-X in­clud­ed Achao­gen and Melin­ta, as well as lo­cal Mass­a­chu­setts play­ers such as Spero, Macrolide, and Tetraphase.

In Short: I Got it Wrong

Oc­ta­gon was able to raise Seed fi­nanc­ing based on our strong da­ta pack­age and founder CVs. How­ev­er, as we put our heads down and be­gan op­ti­miz­ing our in­ter­est­ing chem­i­cal hit, we watched the space fur­ther de­te­ri­o­rate:

  • Spero ($SPRO) had a suc­cess­ful IPO but lost half their mar­ket cap in the sub­se­quent 12 months.
  • No­var­tis an­nounced that they, too, were aban­don­ing all an­tibi­ot­ic de­vel­op­ment ef­forts.
  • Achao­gen ($AKAO) and Paratek ($PRTK) both had NDAs ap­proved for nov­el an­tibi­otics and saw their stock prices drop sharply in re­sponse to the news, as in­vestors an­tic­i­pat­ed all those pesky ex­pens­es re­lat­ed to com­mer­cial­iza­tion.
  • Months lat­er, Achao­gen filed Chap­ter 11. Com­mer­cial stage an­tibi­ot­ic de­vel­op­er Melin­ta is head­ing that way as well.
  • Macrolide piv­ot­ed and re­brand­ed to Zikani (their web­site now has no men­tion of an­tibi­otics).
  • Tetraphase ($TTPH) has a new CEO fo­cused on com­mer­cial­iza­tion but has not been able to make their an­tibi­ot­ic prod­uct prof­itable. They have less than 9 months of cash on hand and pub­lic mar­kets are bet­ting against them.

And these are the suc­cess sto­ries: drug de­vel­op­ment com­pa­nies with the skill and good for­tune to ad­vance a nov­el med­i­cine all the way to ap­proval!

An­tibi­ot­ic com­pa­nies com­pared to the Biotech In­dex in 2018

Click on the im­age to see the full-sized ver­sion

Like so many larg­er bio­phar­ma com­pa­nies, Oc­ta­gon changed course, putting our promis­ing an­tibi­ot­ic pro­gram on the shelf and fo­cus­ing all ef­forts on a re­lat­ed ap­proach to treat­ing au­toim­mu­ni­ty. The choice was not prof­it-max­i­miz­ing; it was ex­is­ten­tial.

Why Did This Hap­pen?

How has the space gone from bad to worse while rates of mul­ti-drug re­sis­tant in­fec­tion and deaths caused by su­per­bugs steadi­ly in­crease? Well, it’s ac­tu­al­ly not en­tire­ly clear how many lives are claimed by lack of ef­fec­tive an­tibi­otics. Pa­tients who con­tract, or suc­cumb to, a re­sis­tant in­fec­tion are se­vere­ly un­der­count­ed. Un­der the Af­ford­able Care Act, hos­pi­tals must pay a penal­ty for each hos­pi­tal-ac­quired-in­fec­tion (HAI) oc­cur­ring with­in their in-pa­tient pop­u­la­tion. As a re­sult, if a pa­tient dies from a su­per­bug con­tract­ed dur­ing a pro­ce­dure such as surgery, the of­fi­cial cause of death may be in­stead list­ed as “Com­pli­ca­tions from Surgery.” Con­sis­tent and sys­temic un­der­count­ing of ill­ness­es and deaths from re­sis­tant in­fec­tions fur­ther dis­cour­ages the de­vel­op­ment of new an­tibi­otics as the num­ber of pa­tients who need these med­i­cines may ap­pear to be very small.

The fail­ure of the mar­ket for new an­tibi­otics has al­so been caused by sev­er­al eco­nom­ic and com­mer­cial fac­tors. Ap­proval in­cen­tives were not the on­ly pol­i­cy in­clud­ed in the GAIN Act. There were al­so mea­sures de­signed to pro­mote stew­ard­ship, or ap­pro­pri­ate use, of new an­tibi­otics. In short, when a new an­tibi­ot­ic be­comes avail­able, it should on­ly be used as a last re­sort to pre­vent new re­sis­tance from aris­ing. This kind of re­spon­si­ble use is a good thing! But stew­ard­ship se­vere­ly lim­its the num­ber of pa­tients who will re­ceive a new an­tibi­ot­ic and, cor­re­spond­ing­ly, the po­ten­tial sales vol­ume.

In­sur­ers pay for in-pa­tient an­tibi­otics as part of a lump sum to hos­pi­tals known as a Di­ag­no­sis Re­lat­ed Group (DRG). Us­ing a cheap an­tibi­ot­ic in­creas­es hos­pi­tal prof­it mar­gins, while us­ing an ex­pen­sive new drug could mean that a hos­pi­tal might lose mon­ey by treat­ing a giv­en pa­tient. As a re­sult, hos­pi­tals are in­cen­tivized to use cheap­er an­tibi­otics when­ev­er pos­si­ble. This puts sig­nif­i­cant pric­ing pres­sure on new an­tibi­otics, which are one of the on­ly type of med­i­cines paid for like this.

As a re­sult, new an­tibi­otics typ­i­cal­ly end up with list prices in the $2,000 — $3,000 range (for a one-time cure!) while pay­ers glad­ly shell out tens or hun­dreds of thou­sands for can­cer drugs or med­i­cines for rare ge­net­ic dis­eases. Low sales vol­umes (due to stew­ard­ship) and low price points (due to DRG-dri­ven pric­ing pres­sures) re­sult in min­i­mal sales for nov­el an­tibi­otics. Achao­gen’s new an­tibi­ot­ic was see­ing unim­pres­sive sales of around a mil­lion dol­lars per quar­ter be­fore the com­pa­ny fold­ed. At these sales fig­ures, the com­pa­ny would have nev­er re­couped the cost of de­vel­op­ing the drug.

Smart Mon­ey is Stay­ing on the Side­lines

This is a com­plete fail­ure of the mar­ket for these crit­i­cal­ly im­por­tant prod­ucts. Pro­grams like CARB-X and the No­vo RE­PAIR Fund, de­signed to fund risky pre­clin­i­cal work and pro­mote da­ta shar­ing, are well-mean­ing but in­suf­fi­cient. An­tibi­otics are just not worth the cost of de­vel­op­ment. With­out a func­tion­ing mar­ket, CARB-X and oth­er grant pro­grams are a bridge to nowhere. Ven­ture cap­i­tal in­vestors know this. VCs will tol­er­ate bi­ol­o­gy risk, they like clin­i­cal risk, but they will not go near a ven­ture where there is ma­jor com­mer­cial risk of fail­ure. Risk cap­i­tal is bet­ter de­ployed to­wards pro­grams ad­dress­ing large num­bers of pa­tients or those that can be ex­pect­ed to re­ceive high price points. No amount of non-di­lu­tive fund­ing can make up for the lack of ven­ture cap­i­tal and growth cap­i­tal in­vest­ment in de­vel­op­ing these med­i­cines. Oc­ta­gon pitched dozens of ven­ture cap­i­tal firms and watched part­ners im­me­di­ate­ly tune out at the men­tion of an­tibi­otics; there is noth­ing worse than an in­vestor meet­ing that is over be­fore it starts.

The lack of ven­ture cap­i­tal in­vest­ment in­to de­vel­op­ing these prod­ucts has fur­ther neg­a­tive con­se­quences. Com­pe­ti­tion for tal­ent is fierce in the biotech ecosys­tem. Cash-strapped an­tibi­ot­ic de­vel­op­ers may be un­able to com­pete with high pro­file VC-backed com­pa­nies on com­pen­sa­tion. The most skilled and am­bi­tious sci­en­tists will rein­vent them­selves, join­ing mi­cro­bio­me com­pa­nies or syn­thet­ic bi­ol­o­gy star­tups where they can ap­ply their mi­cro­bi­ol­o­gy smarts. Oc­ta­gon lost one of our best sci­en­tists to or­gan­ism en­gi­neer­ing com­pa­ny, Gink­go Bioworks. If this trend con­tin­ues, an­tibi­ot­ic dis­cov­ery and de­vel­op­ment may well be­come a lost art.

Pub­lic mea­sures de­signed to in­cen­tivize de­vel­op­ment of new an­tibi­otics are woe­ful­ly in­ad­e­quate. No amount of grant fund­ing will make up for a mar­ket that is hope­less­ly bro­ken. Mer­ck CEO Ken Fra­zier put it well: “Some­times new drugs are not avail­able, not be­cause the price is too high, but be­cause it is too low.” New ideas are be­ing ex­plored, such as sub­scrip­tion mod­els that de­cou­ple sales from vol­ume while guar­an­tee­ing an­nu­al min­i­mums, but these are lit­tle more than thought ex­per­i­ments at present and may on­ly work in sin­gle-pay­er health­care sys­tems.

If our in­dus­try tru­ly be­lieves we have a re­spon­si­bil­i­ty to put pa­tients ahead of prof­its, we need to work to fix this bro­ken mar­ket rather than ig­nor­ing the prob­lem in fa­vor of more prof­itable dis­ease ar­eas. There are ma­jor ex­ter­nal­i­ties dri­ven by ac­cess to new ef­fec­tive an­tibi­otics. With­out the abil­i­ty to treat in­fec­tions, sim­ple pro­ce­dures such as C-sec­tions or hip re­place­ments will present enor­mous risk, and can­cer mor­tal­i­ty rates will sky­rock­et. Sav­ing lives should be good busi­ness but, in this case, it’s not. With­out re­al mar­ket re­form, an­tibi­ot­ic de­vel­op­ment will con­tin­ue to be un­in­vestable, and these med­i­cines will not be avail­able to pa­tients who des­per­ate­ly need them.


Isaac Ston­er is the co-founder of Oc­ta­gon, a drug dis­cov­ery com­pa­ny de­vel­op­ing tar­get­ed meta­bol­ic in­hibitors for au­toim­mune dis­ease. He has spent his ca­reer build­ing ear­ly stage life sci­ences com­pa­nies as a sci­en­tist, op­er­a­tor, and in­vestor. 

Orig­i­nal­ly post­ed on Medi­um

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Alex­ion puts €65M for­ward to strength­en its po­si­tion on the Emer­ald Isle

Ireland has been on a roll in 2022, with several large pharma companies announcing multimillion-euro projects. Now AstraZeneca’s rare disease outfit Alexion is looking to get in on the action.

Alexion on Friday announced a €65 million ($68.8 million) investment in new and enhanced capabilities across two sites in the country, including at College Park in the Dublin suburb of Blanchardstown and the Monksland Industrial Park in the central Irish town of Athlone, according to the Industrial Development Agency of Ireland.

State bat­tles over mifepri­s­tone ac­cess could tie the FDA to any post-Roe cross­roads

As more than a dozen states are now readying so-called “trigger” laws to kick into effect immediate abortion bans following the overturning of Roe v. Wade on Friday, these laws, in the works for more than a decade in some states, will likely kick off even more legal battles as states seek to restrict the use of prescription drug-based abortions.

Since Friday’s SCOTUS opinion to overturn Americans’ constitutional right to an abortion after almost 50 years, reproductive rights lawyers at Planned Parenthood and other organizations have already challenged these trigger laws in Utah and Louisiana. According to the Guttmacher Institute, other states with trigger laws that could take effect include Arkansas, Idaho, Kentucky, Mississippi, Missouri, North Dakota, Oklahoma, South Dakota, Tennessee, Texas, and Wyoming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Deborah Dunsire, Lundbeck CEO

Af­ter a 5-year re­peat PhI­II so­journ, Lund­beck and Ot­su­ka say they're fi­nal­ly ready to pur­sue OK to use Rex­ul­ti against Alzheimer's ag­i­ta­tion

Five years after Lundbeck and their longtime collaborators at Otsuka turned up a mixed set of Phase III data for Rexulti as a treatment for Alzheimer’s dementia-related agitation, they’ve come through with a new pivotal trial success they believe will finally put them on the road to an approval at the FDA. And if they’re right, some analysts believe they’re a short step away from adding more than $500 million in annual sales for the drug, already approved in depression and schizophrenia.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

A Mer­ck part­ner is sucked in­to the fi­nan­cial quag­mire as key lender calls in a note

Another biotech standing on shaky financial legs has fallen victim to the bears.

Merck partner 4D Pharma has reported that a key lender, Oxford Finance, shoved the UK company into administration after calling in a $14 million loan they couldn’t immediately make good on. Trading in their stock was halted with a market cap that had fallen to a mere £30 million.

“Despite the very difficult prevailing market conditions,” 4D reported on Friday, the biotech had been making progress on finding some new financing and turned to Oxford with an alternative late on Thursday and then again Friday morning.

Members of the G7 from left to right: Prime Minister of Italy Mario Draghi, European Commission President Ursula von der Leyen, President Joe Biden, German Chancellor Olaf Scholz, British Prime Minister Boris Johnson, Canadian Prime Minister Justin Trudeau, Prime Minister of Japan Fumio Kishida, French President Emmanuel Macron and European Council President Charles Michel (AP Photo/Susan Walsh)

Biden and G7 na­tions of­fer funds for vac­cine and med­ical prod­uct man­u­fac­tur­ing project in Sene­gal

Amidst recently broader vaccine manufacturing initiatives from the EU and European companies, the G7 summit in the mountains of Bavaria has brought about some positive news for closing vaccine and medical product manufacturing gaps around the globe.

According to a statement from the White House, the G7 leaders have formally launched the partnership for global infrastructure, PGII. The effort will aim to mobilize hundreds of billions of dollars to deliver infrastructure projects in several sectors including the medical and pharmaceutical manufacturing space.

Fed­er­al judge de­nies Bris­tol My­er­s' at­tempt to avoid Cel­gene share­hold­er law­suit

Some Celgene shareholders aren’t happy with how Bristol Myers Squibb’s takeover went down.

On Friday, a New York federal judge ruled that they have a case against the pharma giant, denying a request to dismiss allegations that it purposely slow-rolled Breyanzi’s approval to avoid paying out $6.4 billion in contingent value rights (CVR).

When Bristol Myers put down $74 billion to scoop up Celgene back in 2019, liso-cel — the CAR-T lymphoma treatment now marketed as Breyanzi — was supposedly one of the centerpieces of the deal. After going back and forth on negotiations for about six months, BMS put $6.4 billion into a CVR agreement that required an FDA approval for Zeposia, Breyanzi and Abecma, each by an established date.

Chris Anzalone, Arrowhead CEO

Take­da, Ar­row­head spot­light da­ta from small tri­al show­ing RNAi works in a rare liv­er con­di­tion

Almost two years after Takeda wagered $300 million cash to partner with Arrowhead on an RNAi therapy for a rare disease, the companies are spelling out Phase II data that they believe put them one step closer to their big dreams.

In a small, open label study involving only 16 patients who had liver disease associated with alpha-1 antitrypsin deficiency (AATD), Arrowhead’s candidate — fazirsiran, previously ARO-AAT — spurred substantial reductions in accumulated mutant AAT protein in the liver, a hallmark of the condition. Investigators also tracked improvements in symptoms, with seven out of 12 who received the high, 200 mg dose seeing regression of liver fibrosis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

No stranger to gene ther­a­py woes, Astel­las runs in­to an­oth­er safe­ty-re­lat­ed clin­i­cal hold

Astellas Pharma, which has been at the forefront of uncovering the risks associated with gene therapies delivered by adeno-associated viruses, must take another safety alarm head-on.

The FDA has slapped a clinical hold on Astellas’ Phase I/II trial of a gene therapy candidate for late-onset Pompe disease, after investigators flagged a serious case of peripheral sensory neuropathy.

It marks the latest in a streak of setbacks Astellas has encountered since making a splashy entry into the gene therapy space with its $3 billion buyout of Audentes. But the lead program, AT132 for the treatment of X-linked myotubular myopathy (XLMTM), had to be halted more than once after a total of four patients died in the trial — and the scientific community still doesn’t have all the answers of what caused the deaths.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.